Group 1 - In 2025, out of 650 comparable QDII funds, 619 funds saw an increase in net value, representing 95.2% of the total, while 31 funds experienced a decline [1] - The top-performing fund, Huatai Fuhong Hong Kong Advantage Selection Mixed (QDII) A/C, achieved a remarkable growth of 114.19% and 113.83% respectively [1] - The fund's investment strategy focuses on innovative pharmaceuticals with global competitiveness and high-barrier equipment and consumables [1] Group 2 - The current fund manager of Huatai Fuhong is Zhang Wei, who has extensive experience in the pharmaceutical sector [2] - Six other QDII funds recorded growth exceeding 80%, with four of them managed by E Fund Management, all surpassing 85% growth [2] - The top holdings of these funds include major companies like TSMC, NVIDIA, Google, and Alibaba [2] Group 3 - There are 26 QDII funds with monthly growth rates between 60% and 80%, with the largest being GF Zhongzheng Hong Kong Innovative Medicine ETF (QDII), which had a growth of 66.65% [3] - The Fuguo Blue Chip Selected Stock (QDII) in USD also showed significant growth of 67.99% [4] Group 4 - The bottom-performing QDII funds in 2025 were primarily those focused on oil and gas products, with 10 funds declining over 10% [5] - E Fund Management had four products leading the decline, with losses ranging from 11.64% to 13.59% [5]

Core Insights - The QDII funds market has shown strong performance in the first ten months of the year, with 95.1% of the 650 comparable funds reporting net value increases, while only 32 funds experienced declines [1] Fund Performance - The top-performing QDII funds include Huatai-PineBridge Hong Kong Advantage Selected Mixed A and C, both achieving returns of 117.54% and 117.53% respectively [1] - A total of 10 QDII funds recorded gains exceeding 78%, with E Fund's Global Growth Selected Mixed A and C (USD and RMB) each surpassing 83% [2][3] - The leading funds in the innovation drug sector have significantly contributed to the overall performance, with notable funds like the GF CSI Hong Kong Innovation Drug ETF and others achieving returns between 78.11% and 88.09% [3] Investment Focus - The investment strategy of the top-performing funds emphasizes sectors such as innovative pharmaceuticals and high-barrier medical equipment, targeting companies with global competitiveness and growth potential [1][3] - The top holdings of the leading funds include major players in the biotech and pharmaceutical industries, such as TSMC, NVIDIA, and Alibaba [2][3] Market Trends - The innovation drug sector has rebounded, leading to a broad increase in related stocks, which has positively impacted the performance of funds heavily invested in this area [1][3] - Conversely, funds focused on oil and gas, as well as real estate, have underperformed, indicating a sector rotation within the QDII market [4]

Group 1 - The article emphasizes the importance of investment strategies to achieve financial goals, specifically targeting a tenfold increase from an initial capital of 100,000 to 1,000,000 over ten years [1] - It suggests that relying solely on hard work may not be sufficient to reach financial milestones, and that investing can facilitate wealth accumulation more effectively [1] - The article introduces a specific investment strategy developed by DeepSeek, focusing on a diversified fund portfolio with a maximum of ten funds and a risk tolerance for a 20% drawdown [1][2] Group 2 - The operational strategy includes annual adjustments to the asset allocation, where if any asset class exceeds its target allocation by 5%, a portion is sold and reinvested into underweighted assets like bonds or gold [3] - In extreme market conditions, if the overall portfolio approaches a 20% drawdown, the strategy advises reducing high-volatility assets (such as technology and pharmaceuticals) and increasing holdings in bonds or gold [3] - The article also mentions a core-satellite strategy, suggesting specific funds for consideration, including those focused on global growth and consumption, as well as bond and gold ETFs [4][5]